Emerson Electric (EMR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
17 Apr, 2026Executive summary
Q1 2026 net sales grew 4% year-over-year to $4.3B–$4,346M, with underlying orders up 9% and strong demand in North America, India, and Middle East & Africa, especially in automation and Software & Systems.
Adjusted segment EBITA margin reached 27.7%, and adjusted EPS rose 6% to $1.46, despite a $0.06 headwind from software contract renewals.
Robust growth in Test & Measurement (up 11–14%) and Power verticals, with Life Sciences also strong.
Declared a quarterly dividend of $0.555 per share, payable March 10, 2026.
Annual Contract Value (ACV) of software grew 9% year-over-year to $1.6B.
Financial highlights
Free cash flow for Q1 2026 was $602M, with a margin of 13.9–14%.
Backlog ended at $7.9B, up 9% year-over-year; book-to-bill ratio was 1.13.
Price contributed 3 points to growth; MRO represented 65% of sales.
Gross profit increased 3% to $2.31B; gross margin was 53.2%.
SG&A expenses rose 2% to $1.24B, but as a percent of sales decreased 0.7 pts to 28.6%.
Outlook and guidance
Full-year 2026 guidance: net sales growth ~5.5%, underlying sales growth 4%, adjusted segment EBITA margin ~28%.
Adjusted EPS guidance raised to $6.40–$6.55.
Free cash flow for 2026 expected at $3.5B–$3.6B, margin above 18%.
Q2 sales growth expected at 3–4%, with adjusted EPS of $1.50–$1.55.
Plans to return ~$2.2B to shareholders via ~$1B share repurchases and ~$1.2B dividends.
Latest events from Emerson Electric
- Order growth, AI-driven automation, and software rebound underpin strong long-term outlook.EMR
JPMorgan Industrials Conference 202617 Mar 2026 - AI-driven software growth and robust U.S. demand fuel strong performance and future outlook.EMR
Citi's Global Industrial Tech & Mobility Conference 202618 Feb 2026 - Strong order growth, innovation, and high margins drive a positive outlook and investor confidence.EMR
Barclays 43rd Annual Industrial Select Conference17 Feb 2026 - Targeting $21B sales, 30% EBITA margin, $8.00 EPS, and $10B shareholder returns by 2028.EMR
Investor Update3 Feb 2026 - Director elections and key proposals passed; board declassification did not meet approval threshold.EMR
AGM 20263 Feb 2026 - Q3 sales and adjusted EPS up 11%, Copeland exit boosts debt reduction and guidance raised.EMR
Q3 20242 Feb 2026 - Record FY24 growth, portfolio actions, and $2B buyback set up strong 2025 outlook.EMR
Q4 202416 Jan 2026 - Record margins, 13% EPS growth, and robust cash flow with AspenTech deal pending.EMR
Q1 20259 Jan 2026 - Strong financials, board declassification vote, and ESG progress highlight this year's proxy.EMR
Proxy Filing12 Dec 2025